NCBiotech News

Kymanox has opened a new Formulation Lab to provide formulation development and analytical testing services for pharmaceutical and biotechnology companies moving programs from early research into clinical manufacturing.

Caidya, a global clinical research organization based in Raleigh, has announced it is combining with UK-based CRO Simbec-Orion to create a new platform to accelerate drug development programs and international scale-up. The combined company will operate under the Caidya name, the announcement said.

Durham-based 410 Medical, a medical device company developing new technologies for emergency and critical care, has raised $12 million from investors, including two North Carolina venture capital firms.

More than 100 Research Triangle Park officials and other supporters gathered on Thursday for a celebration at HUB RTP to mark the culmination of a multi-year planning process to chart a new long-range vision for the next half-century of innovation and economic growth in RTP. 

North Carolina State University and NCBiotech were proud to sponsor and welcome the Engineering Biology Research Consortium (EBRC) 10th Annual Meeting to Raleigh from June 1–3, 2026. The meeting brought together engineering and synthetic biology researchers and leaders from across the country and North Carolina to share the latest advances in agriculture and food innovation, biopharmaceutical development, AI-enabled biotechnology, biocomputing, genomic technologies, and more.

Clean Cells, a France-based provider of quality testing services for biopharmaceutical products, will acquire Stem Genomics, which provides next-generation quality controls for stem cell therapy. 

United Therapeutics, a biotechnology company with co-headquarters and manufacturing facilities in Research Triangle Park, has acquired a Boston-area biotech company to boost its efforts in regenerative medicine and organ transplantation.

Two life sciences organizations with operations in North Carolina are planning major expansions that will bring over 1,500 jobs and $1.8 billion in investment to the Greater Charlotte region.

The U.S. Food and Drug Administration selected three biopharma companies with manufacturing sites in North Carolina for a pilot program to help develop new domestic biomanufacturing capabilities.

Mary-Dell Chilton, Ph.D., an American pioneer in plant sciences known as the “Queen of the Agrobacterium,” died on June 24, 2026, in Carrboro, N.C. She was 87 years old.

Chilton’s research in the 1970s and 1980s continues to influence plant biotechnology through her groundbreaking discoveries of the interaction between plants and bacteria.

People living with type 1 diabetes walk a delicate line between taking enough insulin to control blood sugar and taking too much, which can cause dangerously low blood sugar, or hypoglycemia. An investigational liver-targeted insulin called HDV Lispro (HDV-LIS) could make day-to-day blood sugar management easier and safer.

Diazyme Laboratories, Inc. has acquired the business of Carolina Liquid Chemistries Corporation (CLC). CLC is an FDA-registered manufacturer and value-added reseller of chemistry systems and reagents. Founded in 1994 and headquartered in Greensboro, N.C., CLC's business will be integrated into Diazyme’s operations.

United Therapeutics Corporation, a public benefit corporation with co-headquarters in Research Triangle Park, has received U.S. Food and Drug Administration (FDA) clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart xenoheart derived from a pig.

Raleigh-based TARGAN, a privately held innovator of biodevices for the poultry industry, will be acquired by Merck Animal Health, the world’s second-largest animal health company by revenue, for an undisclosed price.

Simulations Plus, Inc., a Durham-based global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, entered into a definitive agreement to be acquired by affiliates of Altaris, LLC, an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, in an all-cash transaction.